Ophthalmic Business News

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Victor Perlroth, MD, CEO of Kodiak Sciences, provides an overview of the company’s ongoing retinal therapy programs.

In previous posts, I discussed the great potential for the use of AI-enabled technology for ophthalmology practice marketing, particularly in the area of marketing content production.

ANI Pharmaceuticals will acquire Alimera Sciences under the terms of a definitive agreement, according to a press release.

Johnson & Johnson Innovation closed a transaction of Series A funding as the co-lead investor in TECLens, an early-stage startup focusing on a non-incisional procedure for refractive correction.

The concept of delayed gratification has been ingrained in us throughout medical school and residency. This mentality can sometimes lead to explosive spending as an attending when one enjoys a significant salary boost.

The FDA granted priority review of the biologics license application for NT-501 as a treatment for macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

The FDA granted breakthrough therapy and regenerative medicine advanced therapy designations for AURN001 for the treatment of corneal edema secondary to corneal endothelial disease, according to a press release from Aurion Biotech.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss leadership in eye care with guest Jack T. Holladay, MD, MSEE, FACS.

“We have enough votes to pull the plug.”

As we enter the second half of 2024, it is important to understand some tax law changes that became effective this year and could affect your retirement savings and tax planning.